Isoptin Sr

Verapamil Hydrochloride, the active ingredient in Isoptin SR, is a calcium channel blocker presented as an oral sustained‑release tablet for oral use. It treats hypertension, angina pectoris and supraventricular arrhythmias in adult patients.

GNH USA supplies Isoptin SR as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoptin SR, a calcium channel blocker, is employed in several cardiovascular conditions.

- Hypertension: reduces peripheral vascular resistance to lower blood pressure. - Angina pectoris: decreases myocardial oxygen demand by lowering heart rate and contractility. - Supraventricular arrhythmias: slows atrioventricular conduction to control heart rhythm.

Adverse reactions to Isoptin SR vary in frequency and severity.

Common Side Effects: - Constipation - Dizziness - Headache - Peripheral edema - Flushing - Nausea

Serious or Rare Side Effects: - Bradycardia - Severe hypotension - Atrioventricular block - Exacerbation of heart failure - Hepatic dysfunction - Anaphylactic or severe allergic reactions

When prescribing Isoptin SR, clinicians should observe several precautionary measures. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Heart rate assessment: monitor for bradycardia, especially in patients with pre‑existing conduction disorders. - Heart failure caution: use with care in patients with reduced ejection fraction, as negative inotropic effect may worsen symptoms. - Drug discontinuation: avoid abrupt cessation to prevent rebound hypertension or tachycardia. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Isoptin SR may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: combined use can cause marked bradycardia and atrioventricular block. - Digoxin: verapamil increases digoxin plasma concentrations, raising the risk of toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): elevate verapamil levels, potentially leading to severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: concurrent therapy may enhance antihypertensive effect and cause electrolyte disturbances. - ACE inhibitors or ARBs: additive blood‑pressure lowering may require dose adjustments. - NSAIDs: may attenuate the antihypertensive response of verapamil.